U.S drug regulator: Warns Sun Pharma

The United States Food and Drug Administration (USFDA) has issued a warning letter

to Sun Pharmaceuticals as the company was found violating manufacturing norms in its Cranbury facility in New Jersey. Sun Pharma has stated that the FDA has withheld approval of pending new drug applications listing the facility as the manufacturer.

However, it is improbable that the decision may have a noteworthy impact on Sun Pharma's operations in the United States. The company's Cranbury plant manufacturers a restricted number of products - primarily four or five controlled substance drugs (or drugs that fall under the narcotics category). A Sun Pharma spokesperson informed that the profit impact would only be in "single-digit million dollars".

Sun Pharma sustained its 2010-11 consolidated sales growth expectation of 18-20 percent over the reported sales of 2009-10.

Ranjit Kapadia, vice-president of institutional research at HDFC Securities said, "The decision of FDA may not have much impact Sun Pharma in terms of revenue, but the sentiment of a warning letter may pull down stocks, in the wake of ongoing manufacturing issues for Caraco,"

Last year in June, Sun Pharma's U.S. subsidiary Caraco's Michigan facilities in Detroit, Farmington Hills, and Wixom were searched by U.S. marshals. The production had to be stopped for alleged violation of manufacturing regulations. The matter has not been resolved and the production is yet to be started.

Sun Pharmaceutical Industries Inc (SPI Inc) is a wholly owned subsidiary of Sun Pharma. The company received the warning letter by the USFDA as a follow-up to the earlier examination of their manufacturing facility in Cranbury which started in February. FDA found current Good Manufacturing Practice (cGMP) regulations were being violated, as per a statement.

"SPI Inc has undertaken immediate corrective actions and intends to respond promptly and timely to the USFDA within 15 working days," said Sun Pharma.

Besides an active ingredient facility, the company has three manufacturing facilities in the U.S. However, most of its supply to the US market is from its FDA-approved Indian manufacturing facilities.

Two years ago, Daiichi Sankyo-owned Ranbaxy Laboratories was also banned by FDA for violating manufacturing norms at two facilities in India. Ranbaxy is yet to receive approval from the regulator.

U.S drug regulator: Warns Sun Pharma

By: White Digital Media

POST COMMENT

Addictive drugs can lead to disasters Helpful Info Maxiderm Patch Vs Ed Drugs Myths About Drug Abuse Understanding the Specifics of Medical Malpractice An Overview of the Medical Procedures used During Gall Bladder Surgery Just What Exactly To Search For In A United Kingdom Drug Rehab And Substance Recovery Center The Devastating Impact Of War On Medicine What To Check For In A United Kingdom Drug Rehab And Drug Recovery Center Outstanding contributions of Biotechnological plants in the world of medicines Six Wrong Ways Eat Eggs To Be Drug How To Choose An Effective Drug / Alcohol Treatment Center? Treatment Of Drug Addiction Due To Mental Depression Is Pretty Hard Are There Risks Paying For Medication Drugs On-line?